What's Happening?
BUILT Biotechnologies, Inc. has been selected as the preferred manufacturing partner for Neochromosome, Inc. clients requiring large-scale DNA builds. As Neochromosome shifts focus to antibody display and cell engineering platforms, BUILT will provide
a seamless transition for DNA-construction projects. BUILT's Regenerative DNA Assembly platform boasts zero build failures, offering reliability and domestic supply-chain resilience. To support this transition, BUILT has expanded its team, adding experienced commercial leaders to ensure continuity and growth. The company is relocating its headquarters to North Fork Research Park in Charlottesville and increasing manufacturing capacity to meet rising demand.
Why It's Important?
The partnership between BUILT Biotechnologies and Neochromosome highlights the growing demand for outsourced DNA production, driven by advancements in genome engineering. BUILT's expansion and team enhancement ensure uninterrupted access to high-fidelity DNA, crucial for ambitious research programs. This collaboration strengthens BUILT's position in the DNA Manufacturing-as-a-Service sector, providing clients with reliable and efficient solutions. The move to a centralized DNA supply chain model eliminates the need for in-house assembly, offering cost-effective and scalable options for researchers.
What's Next?
BUILT Biotechnologies is preparing for an influx of projects from former Neochromosome clients, with manufacturing capacity reserved through the first quarter of 2026. The company aims to support researchers in unlocking new genome-engineering breakthroughs. As BUILT expands its manufacturing space, it will continue to enhance its platform capabilities, ensuring clients receive sequence-perfect DNA constructs. The focus will be on maintaining customer continuity and driving growth in the DNA manufacturing sector.
Beyond the Headlines
The collaboration between BUILT and Neochromosome reflects broader trends in biotechnology, where companies are increasingly outsourcing complex manufacturing processes to specialized providers. This shift allows researchers to focus on innovation and discovery, leveraging advanced technologies without the burden of in-house production. The success of BUILT's model could inspire similar partnerships across the biotech industry, fostering collaboration and accelerating scientific progress.
